Not available
Quote | Zymeworks Inc. (NYSE:ZYME)
Last: | $6.43 |
---|---|
Change Percent: | 0.47% |
Open: | $6.39 |
Close: | $6.43 |
High: | $6.6 |
Low: | $6.23 |
Volume: | 1,007,698 |
Last Trade Date Time: | 12/15/2022 03:41:52 pm |
News | Zymeworks Inc. (NYSE:ZYME)
2024-06-21 09:15:24 ET Summary Jazz Pharmaceuticals plc's suvecaltamide failed in a phase 2b trial for essential tremor, but this is a minor setback for the company and one that should have been expected. The oxybate franchise is performing well despite generic Xyrem and Lumryz co...
2024-06-17 14:49:47 ET More on Zymeworks Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data Zymeworks shares sink after company removes CFO Christopher Astle Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript Zymeworks Q1 2024 Earnin...
Message Board Posts | Zymeworks Inc. (NYSE:ZYME)
Subject | By | Source | When |
---|---|---|---|
50 million complete...... 325 million potential by the | Brokemillwright | investorshub | 11/30/2022 11:36:11 PM |
All the pumpers run away? Can't believe this | Brokemillwright | investorshub | 10/21/2022 1:53:28 AM |
Its been holding up nicely here! Lets | Clean | investorshub | 06/01/2022 1:53:11 PM |
I believe it does still look promising my friend. | DTGoody | investorshub | 05/27/2022 4:27:47 PM |
Howdy $ZYMEers. The future still looks pretty good here, | budgetthis | investorshub | 05/27/2022 3:30:25 PM |
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License A...
2024-05-15 08:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...